Dr. Frank Theobald verrät, wie positive Studienergebnisse, ein beschleunigter API-Screening-Service und kontinuierliche Formatinnovationen die Tür zu neuen Behandlungsmöglichkeiten mit Microarray-Pflastern öffnen.
Dr. Mike Schaefers shares his initial reflections on the company’s hybrid proposition, how it supports customer demand, and how the LTS culture keeps patient need at its core.
LTS LOHMANN Therapie-Systeme AG announces the closing of the acquisition of Tapemark Inc. located in St. Paul, MN, USA.
Our LTS Academy session reports on the latest research in the field of pain and ketamine.
Ketamine is a versatile drug administered via various routes, predominantly intravenously, for a variety of indications, including anesthesia, pain relief and treatment of depression.
With a new regenerative thermal oxidizer, the company saves about 1.5 million kWh per year.
Even the Egyptians explored the topical application of creams for the treatment of skin diseases and for systemic pain relief.
In our LTS Academy session we will report on the [...]
We are happy to announce our new strategic partnership with the 5-HT Digital Hub - Chemistry & Health.
Dr. Julia Lodder-Gadaczek, Director Analytical Development in-vitro studies, talks about her role leading one of the LTS laboratories and how in-vitro models and working practices are continually evolving to provide accelerated, expert support to development partners.
